Ratio Therapeutics

Check out this UroToday + GU OncToday interview between Dr. John Babich, CSO of Ratio, and Dr. Oliver Sartor, Director of Radiopharmaceutical Trials at the Mayo Clinic, where they discuss the potential of radiopharmaceuticals for cancer treatment. https://bit.ly/4g4G8XF

#ICYMI – Ratio co-founders Drs. Jack Hoppin and John Babich recently spoke with Ira S. Pastor of the Progress, Potential, And Possibilities podcast about Ratio’s technology and why diagnostics and therapeutics go hand in hand when developing #radiopharmaceuticals. Watch the full interview: https://lnkd.in/eipMUMch #cancer #interview

#Hiring - Join Ratio Therapeutics as an Experienced Analytical Chemist!   Are you an analytical #chemist with 8+ years of #pharmaceutical experience and a deep understanding of process development? We're looking for someone like you to lead bench science and grow into a technical lead role. #Radiopharmaceutical experience? That's a big plus!   If you're passionate about innovation and want to be part of a team that's pioneering radioligand therapy to improve the lives of cancer patients and their families, we want to hear from you!   Is this you or someone you know? Please apply or share this post! https://lnkd.in/dunfVqh7

Ratio’s fully integrated proprietary R&D platforms, Trillium™ and Macropa™, harness the tumor-killing power of the alpha emitting radionuclide actinium-225 to selectively destroy #cancer cells. Ratio’s Trillium™ technology is a proprietary and innovative platform that modulates drug pharmacokinetics (PK) and improves drug availability, tumor delivery, and tumor loading, while simultaneously reducing the side effects commonly observed with other radiotherapies. Learn more: https://lnkd.in/e--KTJiH #radiopharmaceuticals #theranostics

#Hiring - Join Ratio Therapeutics!   We're on a mission to improve and extend the lives of #cancer patients without compromising their quality of life. We're seeking top talent to join our team of experts developing novel #radiotherapeutics.   ✔️ Dynamic, fast-paced environment ✔️ Global collaboration with researchers ✔️ World-class scientists and professionals   If you're passionate about groundbreaking cancer treatment research and want to make a real impact, we want to hear from you. Let's change the way cancer is treated together!   Visit our website to see open positions: https://lnkd.in/eQdxdGKw

Ratio was recently featured in this C&EN article from Aayushi Pratap about the growing field of #oncology #radiopharmaceuticals. Targeted radiopharmaceuticals are generally composed of a radioactive isotope, a chelating agent, a linker, and a target-binding domain. This article explores the options and considerations for choosing the right isotope. Full article: https://lnkd.in/eSJPySNa

Reminder! Tomorrow, Ratio’s CEO Jack Hoppin will be an expert speaker at the 3rd Annual Targeted Radiopharmaceuticals Summit, taking place July 30 – August 1, 2024 in San Diego, CA. He will be speaking at the following workshops on Tuesday, July 30: ⏱️ 8:30 am: Workshop A | Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy ⏱️ 11 am: Workshop E | Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes For more details and to register, visit: https://lnkd.in/eXjc43na #radiopharmaceuticals #TRP #TRP24

Ratio’s CEO Jack Hoppin will be an expert speaker at the 3rd Annual Targeted Radiopharmaceuticals Summit, taking place July 30 – August 1, 2024 in San Diego, CA. He will be speaking at the following workshops on Tuesday, July 30: ⏱️ 8:30 am: Workshop A | Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy ⏱️ 11 am: Workshop E | Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes For more details and to register, visit: https://lnkd.in/eXjc43na #radiopharmaceuticals #TRP #TRP24

The dynamic landscape of diagnostic and therapeutic radiopharmaceuticals, also known as theranostics, has expanded greatly over the past decade. The Lancet has recently published a series dedicated to this field, covering topics from the latest advances in radiochemistry to the building of global and equitable access to theranostic radiopharmaceuticals. https://lnkd.in/e6XHXa3D #radiopharmaceuticals #theranostics

Ratio’s CEO Jack Hoppin will be an expert speaker at the 3rd Annual Targeted Radiopharmaceuticals Summit, taking place July 30 – August 1, 2024 in San Diego, CA. He will be speaking at the following workshops on Tuesday, July 30: ⏱️ 8:30 am: Workshop A | Evaluating Novel Radiopharmaceutical Targeting Agents for Enhanced Specificity & Efficacy ⏱️ 11 am: Workshop E | Advancing Dosimetry Data: An Invaluable Tool to Optimize Therapeutic Outcomes For more details and to register, visit: https://lnkd.in/eXjc43na #radiopharmaceuticals #TRP #TRP24